Magnitude Biosciences secures new investment to accelerate specialist anti-ageing research services

Magnitude Biosciences Limited, a specialist provider of C. elegans research services to the longevity, nutraceuticals and pharmaceutical industries, has closed a fourth round of investment to accelerate the scaling of its business.

A total investment of £500,000 will be made by longstanding investors the North East (ERDF) Innovation Fund Limited Partnership, supported by the European Regional Development Fund and managed by Northstar Ventures Limited, and Saker Capital LLP.

The Company’s earlier loans totalling £250,000 from the Coronavirus Future Fund (UK FF Nominees Limited), Saker Capital and Northstar Ventures have also been converted as part of this investment round.

The investment has been made in response to rapidly growing customer demand for Magnitude Biosciences’ services. The new funding will enable Magnitude to expand its research facilities, invest in the automation of key processes and grow the scientific, sales and operational teams.

Magnitude Biosciences is poised to benefit from the growth and significant investment in anti-ageing and longevity companies and the growing recognition that C. elegans (a nematode worm) is an ideal organism in which to rapidly identify compounds that could extend life.

The testing services are very cost effective and the output from experiments can be provided in as little as 2 weeks and provide a wealth of experimental data that provide rich insights including not just a compound’s efficacy, but also its mode of action and potential toxicity. The Company’s co-founder and CSO, Dr David Weinkove, is internationally known for his expertise in this field and provides invaluable scientific input to customers wishing to screen their compounds.

Magnitude Biosciences’ chair, Dr Sally Waterman, commented: ’This further investment from Northstar Ventures and Saker Capital will enable us to increase our capacity to work with companies who are developing new therapies and health supplements which could help us have a longer and healthier life.

“The success of the Company so far is a testament to the commitment and expertise of our team and would not have happened without the continued support of our investors’.

By Mark Adair – Correspondent, Bdaily

• Add me on LinkedIn and Twitter to keep up to date
• And follow Bdaily on Facebook, Twitter and LinkedIn
• Submit press releases to editor@bdaily.co.uk for consideration

Looking to promote your product/service to SME businesses in your region? Find out how Bdaily can help →